The cAMP-degrading phosphodiesterase 4 (PDE4) family of enzymes is a potential target for therapeutics for the treatment of chronic obstructive pulmonary disease (COPD), asthma, depression and neurodegenerative diseases. Here, PDE4A is linked to chronic obstructive pulmonary disease.